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Abstract
Aims: High circulating long chain fatty acids (LCFAs) are implicated in diabetic neuropathy (DN) development.
Expression of the long-chain acyl-CoA synthetase 1 (Acsl1) gene, a gene required for LCFA metabolic activation,
is altered in human and mouse diabetic peripheral nerve. We assessed the significance of Acsl1 upregulation in
primary cultured Schwann cells. Results: Acsl1 overexpression prevented oxidative stress (nitrotyrosine; hy-
droxyoctadecadienoic acids [HODEs]) and attenuated cellular injury (TUNEL) in Schwann cells following 12 h
exposure to LCFAs (palmitate, linoleate, and oleate, 100 lM). Acsl1 overexpression potentiated the observed
increase in medium to long-chain acyl-carnitines following 12 h LCFA exposure. Data are consistent with in-
creased mitochondrial LCFA uptake, largely directed to incomplete beta-oxidation. LCFAs uncoupled mito-
chondrial oxygen consumption from ATP production. Acsl1 overexpression corrected mitochondrial
dysfunction, increasing coupling efficiency and decreasing proton leak. Innovation: Schwann cell mitochondrial
function is critical for peripheral nerve function, but research on Schwann cell mitochondrial dysfunction in
response to hyperlipidemia is minimal. We demonstrate that high levels of a physiologically relevant mixture of
LCFAs induce Schwann cell injury, but that improved mitochondrial uptake and metabolism attenuate this
lipotoxicity. Conclusion: Acsl1 overexpression improves Schwann cell function and survival following high
LCFA exposure in vitro; however, the observed endogenous Acsl1 upregulation in peripheral nerve in response
to diabetes is not sufficient to prevent the development of DN in murine models of DN. Therefore, targeted
improvement in Schwann cell metabolic disposal of LCFAs may improve DN phenotypes. Antioxid. Redox Signal.
21, 588–600.
Introduction
Diabetic neuropathy (DN) is a prevalent complicationof diabetes and affects *60% of the 26 million people
with prediabetes and diabetes in the United States (6, 32). The
consequences of DN, including chronic pain or loss of sen-
sation, recurrent foot ulcerations, and amputation, are re-
sponsible for significant morbidity and high economic impact
(10). Dyslipidemia is a recognized risk factor for the devel-
opment of DN (1, 30, 40). Lipid profiles are commonly ab-
normal early in the course of type 2 diabetes and correlate
with the onset of early DN (7). While glucose-induced oxi-
dative stress is a well-studied mechanism underlying the
pathogenesis of DN (16, 19, 26, 36–38), recent data from both
diabetic subjects and murine models of type 2 diabetes
strongly suggest a role for dyslipidemia and lipid-mediated
oxidative stress in the onset and progression of DN (30, 34).
The goal of our research is to understand how both glucose-
and lipid-mediated oxidative stress lead to injury in cells of
the peripheral nervous system, resulting inDN.Our hope is to
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ultimately discover mechanism-based therapies that can
prevent this injury cascade and ameliorate the signs and
symptoms of DN (33, 35–38).
Schwann cells are the support cells of the peripheral ner-
vous system and are required for peripheral nerve health,
maintenance, and recovery from injury. Schwann cell-specific
knockout of the mitochondrial transcription factor A gene
(Tfam) in mice (29) induces peripheral nerve disease that
strikingly resembles that seen in mouse models of DN (25),
highlighting the necessity of normal Schwann cell mitochon-
drial function for long-term support of peripheral axons (8).
Our laboratory has completed a series of microarray studies
on human and mouse diabetic peripheral nerves (13, 21), pri-
marily assessing gene expression changeswithin Schwann cells.
We have found increased mitochondrial long-chain acyl-CoA
synthetase 1 (Acsl1), carnitine palmitoyltransferase 1a (Cpt1a),
carnitine palmitoyltransferase 1b (Cpt1b), and carnitine/acyl-
carnitine translocase (CACT) gene expression in sciatic nerves
(SCN) from a murine model of type 2 diabetes with DN, the
leptin receptor-deficient db/db mouse (21). The proteins en-
coded by these genes are involved in long chain fatty acid
(LCFA) transport across the mitochondrial membrane (14). In
parallel, we discovered the Acsl1 gene is significantly regulated
in sural nerves from patients with diabetes and DN (13). The
encodedAcsl1 enzyme catalyzes the addition of a CoAgroup to
LCFAs of 16–18 carbons in length, a step required for mito-
chondrial uptake and LCFA metabolism (17). Circulating tri-
glycerides and very low density lipoprotein (VLDL)
triglycerides (11) comprised of LCFAs are elevated in diabetes
and serve as substrates for Acsl1. We questioned whether local
Acsl1 upregulation could serve as a protective compensatory
mechanism in DN in response to lipotoxic peripheral nerve
dysfunction.
In the current study, we examined mitochondrial metabo-
lism, oxidative stress, and cellular injury in response to a high
LCFA environment in primary Schwann cells. We report that
high levels of a physiologically relevant mixture of LCFAs
induce mitochondrial dysfunction and oxidative stress in
primary Schwann cells. Acsl1 overexpression significantly
improves mitochondrial function, ameliorates oxidative
stress, and restores Schwann cell viability. We conclude that
Acsl1 overexpression improves Schwann cell function and
survival in an in vitro high LCFA environment. However,
endogenous Acsl1 upregulation in the db/db mouse SCN is
not sufficient to prevent the development of DN in the com-
plex and chronic in vivo diabetic environment. Our data
support the growing body of literature that lipotoxicity is a
pathomechanism underlying DN and suggest that therapeu-
tically targeting Schwann cell metabolic disposal of LCFAs
could provide a novel therapy for DN.
Results
db/db mice exhibit hypertriglyceridemia, nerve-specific
oxidative stress, and Acsl1 protein upregulation
A mutation in the leptin receptor of the db/db mouse re-
sults in hyperphagia, severe obesity, hyperlipidemia, hyper-
insulinemia, and hyperglycemia beginning at *4 weeks of
age ( Jackson Laboratories; 000642). Significant increases in
oxidative modification were observed in db/db mouse SCN
extracts compared with those of their age-matched controls,
as evidenced by increased nitrotyrosine (nitrosylated pro-
teins) and increased hydroxyoctadecadienoic acids (HODEs)
(lipid peroxidation) (Supplementary Fig. S1A, B; Supple-
mentary Data are available online at www.liebertpub.com/
ars). Significant elevation of fasting plasma triglycerides in
db/db mice at 8 and 24 weeks of age compared with age-
matched db/ + controls ( p < 0.01) was also confirmed, with
this diabetic elevation significantly increased between 8 and
24 weeks of age ( p< 0.01) (Supplementary Fig. S1C). We
performed fast protein liquid chromatography (FPLC) frac-
tionation to compare the plasma lipoprotein profiles and
confirmed these triglycerides are predominantly held within
the VLDL class of lipoproteins (Supplementary Fig. S1D).
VLDL triglycerides are comprised of LCFAs and are thus
substrates for Acsl1, leading us to explore the significance of
regulated Acsl1 gene expression in the db/db SCN. To verify
that the upregulated mRNA is translated to a biological pro-
tein, we performedWestern immunoblotting on homogenized
whole SCN (Fig. 1). Acsl1 protein expression was significantly
increased in db/db SCN compared with age-matched db/+
SCN (8 weeks, 3.5-fold increase, p< 0.05; 24 weeks, 4.0-fold
increase, p< 0.01). Together, these data confirm that the db/
db type 2 diabetes mouse model exhibits altered triglyceride
profiles and oxidative modifications that are correlated with
Acsl1 gene and protein regulation.
Incubation in high LCFAs increases Acsl1 protein
expression in primary cultured Schwann cells
To examine the relationship between LCFAmetabolism and
Acsl1 expression in vitro, we used primary Schwann cell cul-
tures. We confirm that Schwann cells express Acsl1 protein
under basal media conditions (5.5mM glucose) (Supplemen-
tary Fig. S2). In response to incubation in highLCFA (+ 100lM)
media, Schwann cells increase Acsl1 protein expression by 2.7-
fold ( p< 0.001) (Fig. 2). These data confirm that Acsl1 protein is
expressed in cultured Schwann cells (Supplementary Fig. S2)
and increased in response to high LCFAs (Fig. 2).
LCFA-induced increases in mitochondrial transport
genes and metabolites of beta-oxidation
are potentiated by Acsl1 overexpression
Wenext examined the effects of lentiviral overexpression of
Acsl1 on specific responses to LCFAs. Overexpression was
Innovation
Schwann cell mitochondrial function is critical for pe-
ripheral nerve function. Hypertriglyceridemia and ele-
vated circulating long chain fatty acids (LCFAs) are
implicated in type 2 diabetic neuropathy (DN) pathology,
however, there is little research focusing on Schwann
cell mitochondrial dysfunction in response to a high
LCFA environment. We demonstrate that high levels of a
physiologically-relevant mixture of saturated, monoun-
saturated, and polyunsaturated LCFAs induce mitochon-
drial bioenergetic changes associated with oxidative stress
and cellular injury in primary cultured Schwann cells, and
that improved mitochondrial metabolism of LCFAs at-
tenuate this lipotoxicity. Targeted improvement in
Schwann cell mitochondrial metabolic disposal of LCFAs
may therefore have implications for the treatment of DN.
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confirmed by visual confirmation of simultaneously-
expressed mCherry fluorescence (data not shown) and via
Western immunoblot (Supplementary Fig. S3). Subcellular
fractionation of Schwann cell pellets followed by Western
immunoblotting confirmed mitochondrial enrichment of the
overexpressed Acsl1 (Supplementary Fig. S4).
Mitochondrial LCFAmetabolism first requires transport of
Acsl1-activated LCFAs into the mitochondria, and the rate-
limiting enzyme in this process is Cpt1. Real-time PCR (RT-
PCR) was performed for Acsl1 and the three known Cpt1
isoforms. Exposure to LCFAs increasedmRNA levels ofAcsl1,
Cpt1a, Cpt1b, and Cpt1c compared with control media (Fig. 3).
Further, Acsl1 overexpression significantly increased these
LCFA-induced changes in Cpt1a and Cpt1b transcription
( p< 0.05) (Fig. 3).
Once the activated LCFAs (acyl-CoAs) have entered the
mitochondrial matrix, they undergo consecutive turns of
beta oxidation, removing two carbons in the form of acetyl-
CoAwith each cycle. The consecutively shortened acyl-CoAs
can be completely converted to acetyl-CoA through beta-
oxidation cycling, or can be directed to form acyl-carnitines
at any stage. To begin to assess the metabolic fate of Acsl1-
activated LCFAs, we performed directed liquid chromatog-
raphy triple quadrupole mass spectrometry (LC/MS/MS)
FIG. 1. Acsl1 protein expression is in-
creased in db/db SCN at 8 and 24 weeks of
age. The expression of Acsl1 protein in 10lg
homogenized SCN from control (db/+ ) and
diabetic (db/db) mice was determined with
Western immunoblotting (A). Pixel density of
the Acsl1 band in each condition was nor-
malized to the corresponding GAPDH band
(B). Data are mean– SEM for four nerves
per group. *p< 0.05, **p< 0.01 versus age-
matched db/+ . GAPDH, glyceraldehyde-
3-phosphate dehydrogenase; SCN, sciatic
nerve.
FIG. 2. Incubation in high LCFAs in-
creases Acsl1 protein expression in primary
cultured Schwann cells. Schwann cells were
incubated in control defined media, defined
media containing + 100 lM LCFA (for a total
concentration of 100lM) for 12 h. Cells were
harvested and a Western immunoblot was
performed using 20 lg Schwann cell protein
lysate (A). Pixel density of the Acsl1 band in
each condition was normalized to the corre-
sponding GAPDH band (B). High LCFAs
(FA) increased Acsl1 expression 2.7-fold
above control media. Data are mean – SEM,
n= 3 replicate cultures, ***p< 0.001 versus
control. LCFAs, long chain fatty acids.
590 HINDER ET AL.
for acetyl-CoA, acetyl-carnitine, and medium to long-chain
acyl-carnitines on control and Acsl1-overexpressing
Schwann cells incubated with 100 lM LCFA for 12 h (con-
trol + FA or Acsl1 + FA, respectively). High LCFAs were
associated with a significant increase in Schwann cell acetyl-
CoA ( p < 0.001), acetyl-carnitine ( p < 0.05), and medium to
long-chain acyl-carnitines (dodecanoylcarnitine, C12,
p < 0.05; myristoylcarnitine, C14, p < 0.01; palmitoylcarnitine,
C16, p < 0.001) (Fig. 4A, B, F–H). This effect of high LCFAs is
further increased by Acsl1 overexpression, with all mea-
sured metabolites significantly greater in the Acsl1 + FA
Schwann cells compared with the control + FA cells ( p £ 0.05
for all metabolites) (Fig. 4). Together, these findings confirm
that Acsl1 potentiates LCFA mitochondrial transport and
has an effect on LCFA metabolism.
Measurement of mitochondrial function in primary
cultured Schwann cells
To determine the impact of these changes onmitochondrial
bioenergetic function, the bioenergetic profile of control and
Acsl1-overexpressing Schwann cells incubated in control-
defined media or defined media containing + 100 lM LCFA
for 12 h was determined using the XF24 Analyzer following
the sequential addition of oligomycin (ATP synthase inhibi-
tor), carbonyl cyanide-p-trifluoromethoxyphenylhydrazone
(FCCP) (uncoupling protonophore), and antimycin (complex
III inhibitor) (Fig. 5).
The oxygen consumption rate (OCR) remaining following
antimycin A addition (1lM) gives a measure of non-
mitochondrial respiration. Nonmitochondrial Schwann cell
oxygen consumption is unaffected by LCFA treatment or
Acsl1 overexpression (derived from Fig. 5A, B) (Control
3.3 – 0.3; Control + FA 3.4 – 0.4; Acsl1 3.4 – 0.5; Acsl1+ FA
2.9 – 0.4 pMoles/min/lg protein). LCFA treatment was as-
sociated with significant decreases in coupling efficiency (Fig.
5F), respiratory control ratio (Fig. 5G) and spare respiratory
capacity (Fig. 5E). Acsl1 overexpression significantly attenu-
ated this LCFA-induced effect on coupling efficiency (Fig. 5F)
( p < 0.05). Extracellular acidification rate (ECAR) (a measure
of glycolysis) was not significantly different between groups,
indicating no effect of LCFAs or Acsl1 overexpression on
glycolysis (data not shown). These data suggest an improve-
ment in basal mitochondrial efficiency (less proton leak, more
ATP-linked respiration) in LCFA-treated Acsl1 cells com-
pared with LCFA-treated control cells.
To allow us to assess the implications of these changes on
dynamic cellular bioenergetics, these oxygen consumption
data are expressed in terms of maximal respiratory capacity
(FCCP response) in the respective groups (Fig. 6). Compar-
ison of charts between untreated and LCFA-treated control
cells (Fig. 6A, B) shows a 23% increase in proton leak (14% to
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FIG. 3. LCFA-induced increase in Schwann cell mitochondrial transport genes is potentiated by Acsl1 overexpression.
Control and Acsl1-overexpressing Schwann cells were incubated in defined media and defined media containing + 100 lM
LCFAs (Control + FA and Acsl1 +FA, respectively) for 12 h. Cells were harvested in RLT buffer and real-time PCR (RT-PCR)
was performed on isolated RNA. mRNA levels are expressed as a fold-change in relative mRNA expression for control and
Acsl1 cells incubated in high LCFAs compared with cells incubated in control defined media (A) These data are expressed as
a log2 transformation for improved visual comparison (B) Acsl1 overexpression significantly increased LCFA-induced
changes in transcription of Cpt1a and Cpt1b. Data are mean – SEM. *p< 0.05 versus Ctrl+ FA. Cpt1a, carnitine palmitoyl-
transferase 1a; Cpt1b, carnitine palmitoyltransferase 1b.
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37%), with a decrease in spare respiratory capacity of a similar
magnitude (43% to 21%). TheATP-linked oxygen consumption
is maintained in terms of maximal cellular respiratory capacity
(33% to 29%). Comparison of data between LCFA-treated
control and Acsl1-overexpressing cells (Fig. 6B, D) shows that
Acsl1 overexpression normalizes proton leak (37% to 18%),
spare respiratory capacity (21% to 40%), and ATP-linked oxy-
gen consumption (29% to 33%) to untreated control levels (Fig.
6A). Nonmitochondrial oxygen consumption was unaffected
by 12h exposure to high LCFA or by Acsl1 overexpression.
Together, these data indicate that Acsl1 expression impacts
mitochondrial bioenergetic function in response to LCFA ex-
posure by improving mitochondrial coupling efficiency, and
improving spare respiratory capacity.
Acsl1 overexpression does not increase
mitochondrial mass
To assess the contribution of adaptive effects on mito-
chondrial biogenesis to the improved mitochondrial bioen-
ergetic profile, we examined changes inmtDNA expression as
a measure of mitochondrial biogenesis. Twelve hours LCFA
treatment significantly decreasedmtDNA expression, with no
significant effect of Acsl1 overexpression (Supplementary
Fig. S5). These data suggest that the improvements in
bioenergetic parameters are not due to an increase in mito-
chondrial mass.
Acsl1 overexpression protects against LCFA-induced
oxidative stress and cellular injury in primary cultured
Schwann cells
Finally, to assess whether Acsl1 is a modifier of LCFA-
induced lipotoxicity, we examined the effects of Acsl1 over-
expression on oxidative stress and cell viability changes in
response to LCFAs using CellROX Green Reagent, FPLC
quantification of nitrotyrosine (nitrosylated proteins) and
HODEs (lipid peroxidation), and the TUNEL assay. CellROX
Green Reagent was used to assess cellular reactive oxygen
species (ROS) production in control (empty vector) andAcsl1-
overexpressing (Acsl1) Schwann cells. Thirty lM LCFA in-
creased CellROX signal in control cells after 1 h (Fig. 7). This
LCFA treatment effect was attenuated with Acsl1 over-
expression and with 3 h pretreatment in antioxidants that
target global cellular oxidative stress (Fig. 7). This pro-oxidant
effect of LCFA was maintained following 12 h in high LCFA
media (100 lM LCFA), with nitrotyrosine and HODEs levels
increased by 3.5-fold ( p < 0.05) and 2.3-fold ( p< 0.01), re-
spectively in control Schwann cells (Fig. 8A, B). This LCFA-
induced increase in markers of protein and lipid oxidative
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FIG. 4. LCFA-induced increase in Schwann cell mitochondrial metabolites is potentiated by Acsl1 overexpression.
Control and Acsl1-overexpressing Schwann cells were incubated in defined media and defined media containing + 100 lM
fatty acids (Control + FA and Acsl1 + FA, respectively) for 12 h. Cells were snap frozen with liquid nitrogen and directed LC/
MS/MS was performed for the presented metabolites. LCFAs (100 lM) significantly increased Schwann cell acetyl-CoA (A),
acetyl-carnitine (B), and medium to long-chain acyl-carnitines (F–H). Acsl1 overexpression significantly increased this LCFA-
mediated response (A–H). Data are mean – SEM. *p< 0.05, **p < 0.01, ***p< 0.001 versus Ctrl; xxp< 0.01, xxxp< 0.001 versus
Ctrl + FA; {p < 0.05, {{{p< 0.001 versus Acsl1. LC/MS/MS, liquid chromatography triple quadrupole mass spectrometry.
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stress did not occur in Acsl1-overexpressing cells; levels
of nitrotyrosine and HODEs in LCFA-treated Acsl1-
overexpressing cells and untreated control cells were not
significantly different (Fig. 8A, B). One hundred lM LCFAs
was associated with almost 100% TUNEL positivity in control
cells ( p< 0.001 compared with untreated control cells), while
in Acsl1-overexpressing Schwann cells only 15% of LCFA-
treated cells were TUNEL positive ( p< 0.001 compared with
untreated Acsl1-overexpressing cells) (Fig. 8C). These data
suggest that the LCFA-induced increase in oxidative stress in
control Schwann cells is injurious and can be blocked by anti-
oxidant pretreatment.
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FIG. 5. Measurement of mitochondrial function in primary cultured Schwann cells using the XF24 Analyzer. OCR was
measured at basal level and with the sequential addition of oligomycin (1.25 lM), FCCP (300 nM), and antimycin (1lM) to
control (A) and Acsl1-overexpressing (B) Schwann cells following a 12 h incubation in + 100 lM LCFAs (+ FA). OCR levels
are normalized to lg protein. The OCR measurements in (A) and (B) are plotted in (C) and (D) as a percentage of baseline
respiration. Basal OCR (E), coupling efficiency (F), respiratory control ratio (G), and spare respiratory capacity (H) were
calculated after subtracting nonmitochondrial respiration as described in (1). Data are mean– SEM of 3 replicate cultures,
with 10 replicate measures (10 wells) per condition per experiment; *p < 0.05, **p< 0.01 versus Ctrl; xp< 0.05 versus Ctrl + FA;
{p< 0.05, {{p< 0.01, {{{p< 0.001 versus Acsl1. FCCP, carbonyl cyanide-p-trifluoromethoxyphenylhydrazone; OCR, oxygen
consumption rate.
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Discussion
High circulating triglycerides and LCFAs are implicated in
the development and progression of DN (1, 7, 34, 40). Mi-
croarray studies have allowed us to explore the role of
hyperlipidemia-driven gene changes in the diabetic periph-
eral nerve (13, 21). Given that Schwann cells are the primary
cellular components of peripheral nerves (28) and Schwann
cell dysfunction contributes to DN (8), we sought to under-
stand the implications of our identified gene changes on
Schwann cell function and survival. Post-hoc analysis of mi-
croarray data uncovered cross-species regulation of Acsl1 in
both human and mouse diabetic peripheral nerves (13, 21). In
a murine model of type 2 diabetes with elevated VLDL tri-
glycerides, the db/db mouse (Supplementary Fig. S1D), we
confirmed that Acsl1 gene upregulation translates to an in-
crease in Acsl1 protein expression (Fig. 1). In parallel, we also
observed significant increases in both protein and lipid oxi-
dative modifications in SCN from db/db mice (Supplemen-
tary Fig. S1A, B), supporting our contention that oxidative
stress is a major mechanism of hyperglycemia- and lipid-
induced DN in humans and rodents, particularly through the
oxidation of proteins and lipids (32, 34, 39). In the current
study, we explored the biological significance of Acsl1 over-
expression in DN and the intersection of Acsl1 activity and
oxidative stress as an underlying mechanism in DN.
Acsl1 is required for metabolic activation of LCFAs, a
process necessary for LCFA entry into mitochondrial beta-
oxidation (17). We demonstrated that Acsl1 protein is ex-
pressed in primary Schwann cells in vitro (Supplementary Fig.
S2), and that Ascl1 levels are increased in response to high
LCFAs (Fig. 2). These data suggest that modulation of LCFA
metabolism by Acsl1 in Schwann cells may be instrumental in
maintaining normal nerve homeostasis and in response to
elevated LCFAs, commonly seen in type 2 diabetes, there is a
compensatory increase in Ascl1. Given the increased levels of
Acsl1 after LCFA treatment, we next explored whether this
translated to increased mitochondrial uptake andmetabolism
of LCFAs.
Mitochondrial LCFAmetabolism first requires transport of
Acsl1-activated LCFAs into the mitochondria. We therefore
overexpressed Ascl1 in primary Schwann cells (Supplemen-
tary Figs. S3 and S4) concurrent to LCFA treatment to inves-
tigate changes in LCFA transport. The transport proteins
involved are Cpt1, Cpt2, and CACT, where Cpt1 is the
rate-limiting enzyme of the complex (14). We observed
FIG. 6. Parameters of Schwann cell mitochondrial function expressed as percentage maximal respiratory capacity. (A–D)
Illustrate the parameters of mitochondrial function (spare respiratory capacity, ATP-linked O2 consumption, proton leak, and
nonmitochondrial O2 consumption) expressed as a percentage of maximal OCR (FCCP response) from each of the respective
groups of Schwann cells. (A) Control cells, (B) control + 100lM LCFAs (Control + FA), (C) Acsl1-overexpressing cells, (D)
Acsl1-overexpressing cells+ 100 lM LCFAs (Acsl1 + FA).
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LCFA-induced transcriptional upregulation of Cpt1, which is
potentiated byAcsl1 overexpression (Fig. 3). This is consistent
with the finding that palmitic, oleic, and linoleic acids, either
directly or in their activated acyl-CoA forms, each markedly
induce Cpt1 gene expression in the pancreatic beta cell line
INS-1 (3).
Once the activated LCFAs (acyl-CoAs) have entered the
mitochondrial matrix, they undergo consecutive cycles of beta
oxidation. Each cycle shortens the acyl-CoA chain by two
carbons in the form of acetyl-CoA, and produces reducing
equivalents (NADH, FADH2) for oxidative phosphorylation.
The acyl-CoAs can be completely catabolized to acetyl-CoA
when reducing equivalents are required for ATP produc-
tion, or they can be directed away from beta-oxidation and
oxidative phosphorylation to form acyl-carnitines and acetyl-
carnitine. We observed an increase in acetyl-CoA, acetyl-
carnitine, andmedium to long-chain acyl-carnitines following
LCFA treatment (Fig. 4). Our data suggest that the LCFA are
entering the mitochondrial matrix, and entering the beta-
oxidation cycle. This is in agreement with the report that
LCFA-induced Cpt1 gene upregulation leads to increased
activity of Cpt1 and a higher LCFA oxidation capacity in INS-
1 cells (3). However, after a limited number of turns (based
on the species we see that is, medium to long-chain acyl-
carnitines), the LCFA are not fully catabolized through beta-
oxidation. Overexpression of Acsl1 leads to a potentiation of
this response, suggesting that Acsl1 is not only promoting
mitochondrial metabolism of LCFAs, but is also increasing the
direction of acyl-CoAs to acyl-carnitine production (Fig. 4). In
parallel, we also observed that Acsl1 overexpression amelio-
rated LCFA-induced cellular injury (Fig. 8C), further sup-
porting the idea thatAcsl1 overexpression leads to an increase
in incomplete beta-oxidation of LCFA and diverts unrequired
energy substrates from oxidative phosphorylation to offer
protection from electron transport chain overload (5).
Electron transport overload is associated with increased
proton leak, resulting in mitochondrial uncoupling and re-
duced mitochondrial efficiency (5, 37). Therefore, we per-
formed bioenergetic profiling to assess the impact of high
LCFA treatment onmitochondrial function.We observed that
12 h LCFA treatment significantly decreased mitochondrial
efficiency via uncoupling oxygen consumption from ATP
production (Fig. 5). The resulting mitochondrial substrate
overload is associated with increased mitochondrial dys-
function in a number of cell types (5, 26). Further, in primary
Schwann cells, hyperglycemic conditions decrease
FIG. 7. Acsl1 over-
expression and antioxidant
pretreatment protect against
LCFA-induced oxidative stress
in Schwann cells. CellROX
Green Reagent was used to
assess ROS production in
Control (empty vector) and
Acsl1-overexpressing (Acsl1)
Schwann cells. Following a
3 h pretreatment with antiox-
idants ( +AO) (N-acetyl-L-
cysteine, 30mM; alpha-lipoic
acid, 500lM; and catalase,
500U/ml), Schwann cells
were incubated with LCFA
(30 lM FA) or menadione
(100 lM) for 1 h. The level of
ROS production was assessed
by staining green (white ar-
rows) with CellROX Green
Reagent, and nuclei visual-
ized using dapi. Scale bar is
100 lm. ROS, reactive oxygen
species.
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mitochondrial efficiency via uncoupling oxygen consumption
fromATP production, while also decreasing spare respiratory
capacity (41). Under these hyperglycemic conditions there is a
concurrent increase in the ECAR, suggesting that Schwann
cells shift to glycolytic metabolism in a hyperglycemic envi-
ronment (41). Importantly, we did not observe any significant
changes in ECAR (data not shown) in the current study, in-
dicating that Schwann cells did not compensate for the de-
crease in ATP-coupled mitochondrial respiration by
increasing glycolysis.
Another measure of mitochondrial energetic status is spare
respiratory capacity, which represents the cells ability to re-
spond to changes in bioenergetic needs. We observed a de-
crease in the spare respiratory capacity of the Schwann cells
following LCFA treatment (Fig. 5). A decrease in spare re-
spiratory capacity limits the ability of cells to respond to
changes in bioenergetic needs (4), suggesting that the LCFA-
treated Schwann cells are less able to respond to changes in
metabolic load. This decrease in spare respiratory capacity
was also reported in hyperglycemia-treated Schwann cells
(41); however, under hyperglycemic conditions, the cells have
the potential to utilize glycolysis to produce ATP in response
to changes in energy demands. Taken together, the increased
incomplete beta-oxidation (Fig. 4), uncoupling of oxygen
consumption from ATP production, and decreased spare re-
spiratory capacity following LCFA treatment (Figs. 5 and 6)
suggest a LCFA-induced mitochondrial bioenergetic crisis,
which ultimately results in Schwann cell injury (Fig. 8C). Our
data strongly suggest that Acsl1 is instrumental in modulat-
ing the Schwann cell response to the observed LCFA-induced
lipotoxicity. Overexpression of Acsl1 normalized ATP-linked
oxygen consumption and proton leak, and hence, coupling
efficiency (Figs. 5 and 6). In addition, with respect to the in-
creased incomplete beta-oxidation (Fig. 4), mitochondrial
function was normal in Acsl1-overexpressing cells despite
12 h of LCFA-treatment when compared with LCFA-treated
control cells (Figs. 5 and 6). These data suggest that mito-
chondria in Acsl1-overexpressing cells are able to direct sur-
plus energy substrates to acyl-carnitines rather than direct the
reducing equivalents to the electron transport chain, perhaps
decreasing the energetic overload on the electron transport
chain.
Finally, we hypothesized that overexpression of Acsl1
would decrease both oxidative stress and cellular injury in
response to LCFAs. As a first step, we examined the effects of
LCFA treatment on empty vector control cells. In LCFA-
treated control Schwann cells, we demonstrated an increase in
Schwann cell ROS production after only 1 h exposure to LCFA
(Fig. 7), and after 12 h exposure to 100 lM LCFAswe observed
oxidative damage to both proteins and lipids (Fig. 8A, B) and
significant cellular injury (Fig. 8C). Our data in control
Schwann cells are consistent with reports that overwhelming
mitochondrial substrate load is associated with increased
oxidative stress and cellular apoptosis (5, 26). Our data are
also consistent with the report that palmitate is lipotoxic to
immortalized cultured Schwann cells, with ROS production
significantly and persistently elevated from 12h onward fol-
lowing 150 lM palmitate exposure (20). Pretreatment of
control Schwann cells with the antioxidant cocktail (N-acetyl-
L-cysteine, alpha-lipoic acid, and catalase) blocked LCFA-
mediated oxidative stress (Fig. 7). These data agree with our
own previous reports that increasing endogenous antioxidant
defense in Schwann cells prevents oxidative mediated dam-
age (35).
As predicted, Acsl1 overexpression prevented LCFA-
mediated oxidative stress in Schwann cells (Figs. 7 and 8A, B)
and attenuated Schwann cell injury (Fig. 8C). These data
further support our contention that Acsl1 overexpression di-
verts surplus energy away from oxidative phosphorylation,
preventing mitochondrial overload, bioenergetics failure, and
ROS and cellular oxidative damage. Alternatively, it could be
that Acsl1 is promoting LCFAuptake from the cytosol into the
mitochondria, with a corresponding decrease in cytosolic
oxidative stress. This idea is supported by reports that oleate-
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FIG. 8. Acsl1 overexpression protects against LCFA-induced oxidative stress and cellular injury in Schwann cells. Control
and Acsl1-overexpressing Schwann cells were exposed to high LCFAs (FA; 100lM) for 12 h. Protein nitration (nitrotyrosine) (A)
and lipid peroxidation (HODEs) (B) were assessed in Schwann cell samples by reverse-phase high-performance liquid chro-
matography. Treatment of control cells with + 100lM LCFAs (Control+FA) for 12h increased nitrotyrosine andHODEs by 3.50-
fold and 2.3-fold, respectively. Nitrotyrosine andHODEs levels inAcsl1-overexpressing cells did not differ fromuntreated control
Schwann cells, even in the presence of 100lMLCFAs (Acsl1+FA). Cellular injurywas quantitated byTUNEL assay and is plotted
as percentage TUNEL-positive cells (C). After LCFA treatment, almost 100%of control cellswere TUNELpositive,while only 15%
of Acsl1-overexpressing cells were TUNEL positive. Data are mean– SEM, n= 3 replicate cultures, *p< 0.05, **p< 0.01, ***p< 0.001
versus Ctrl; xp< 0.05, xxp< 0.01, xxxp< 0.001 versus Ctrl+FA; {{{p< 0.001 versus Acsl1. HODEs, hydroxyoctadecadienoic acids.
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facilitated clearance of palmitate from the cytosol attenuates
palmitate-induced oxidative stress, endoplasmic reticulum
stress, and apoptosis in myocytes (18). The contribution of
increased cytosolic clearance and decreased endoplasmic re-
ticulum stress to our understanding of Acsl1 action on
Schwann cells will be the focus of future experiments.
In summary, we report that Acsl1 overexpression normal-
ized high LCFA-induced mitochondrial dysfunction and ox-
idative stress, significantly improving Schwann cell viability.
We postulate that this is due to (i) increased mitochondrial
LCFA activation and entry into the mitochondrial matrix,
without direction of excess substrate to the electron transport
chain and (ii) decreased cytosolic LCFAs, reducing cellular
oxidative stress. Our data suggest that Acsl1 upregulation
may be a compensatory response to elevated LCFAs in
Schwann cells, and that extreme Acsl1 upregulation allows
the cells to cope with high LCFAs. However, endogenous
upregulation is not sufficient to prevent lipotoxicity in either
cultured Schwann cells or db/db mouse SCN. If this endog-
enous compensation can be amplified by drug intervention,
targeted improvement in Schwann cell mitochondrial meta-
bolic disposal of LCFAs may have implications for altering
DN phenotypes.
Materials and Methods
Materials
Chemicals were purchased from Sigma-Aldrich Corp. or
Fisher Scientific unless otherwise stated.
Diabetic mice
Male type 2 diabetic (BKS.Cg-m+/+Leprdb; db/db) and
control (db/+ ) mice were purchased from Jackson Labora-
tories. A mutation in the leptin receptor of the db/db mouse
results in hyperphagia, severe obesity, hyperinsulinemia, and
hyperglycemia beginning at 4 weeks of age ( Jackson Labora-
tories; 000642). At 24 weeks of age (20 weeks of diabetes), db/
dbmice exhibit insensitivity tomechanical and thermal stimuli,
along with slowed nerve conduction velocities and reduced
intraepidermal nerve fiber density Sullivan et al. (25). Animals
were maintained at the University of Michigan in a pathogen-
free environment and cared for following the University of
Michigan Committee on the Care and Use of Animals guide-
lines. Mice were given continuous access to food (Purina 5001;
Purina Mills LLC) and water.
Terminal metabolic phenotyping and SCN collection
Micewere euthanized by sodiumpentobarbital overdose at
8 and 24 weeks of age (6 db/+ and db/db at 8 weeks; 6 db/+
and db/db at 24 weeks). The left and right SCN were dis-
sected. The left SCN was frozen in liquid nitrogen and stored
at - 80C until Western immunoblotting was performed. The
right SCN was prepared for quantification of markers of ox-
idative damage as previously described (12). Plasma was
collected for total triglyceride and lipoprotein triglyceride
measurements as previously described (11).
Acsl1 plasmid and lentivirus production
Total RNA was extracted from frozen mouse spinal cord
from C57BL/6 mice using the RNeasy RNA extraction kit
(Qiagen). cDNA was obtained by reverse transcription with
the IScript cDNA synthesis kit (Bio-Rad) using 1 lg of total
RNA in a 20ll reaction according to the manufacturer’s
protocol. The cDNA was diluted 1:5 with ddH2O. Acsl1 was
amplified by PCR in a 50ll reaction using 1 ll of the diluted
mouse spinal cord cDNA, 2ll of 10mM dNTPs (Denville
Scientific, Inc.) (final concentration 200lM each), 5 ·Phusion
HF buffer, Phusion High-Fidelity DNA polymerase (New
England BioLabs), and 50 pmol of forward and reverse
primers: 5¢-CGGGATCCATGGAAGTCCATGAATTGTT-3
and 5¢-GTTTAGCGGCCGCAATTAGATCTTGATGGTGG
CGTA-3¢ (Integrated DNA Technologies). The following
thermocycler protocol was used for the reaction: 98C for 30 s,
(98C for 5 s, 55C for 30 s, 72C for 30 s) · 30 cycles; and a final
extension of 72C for 10min. The amplified product was di-
rectionally cloned into BamH1 and Not1 of the pLVX-IRES-
mCherry vector (Clontech). The construct was confirmed by
sequencing at the University of Michigan Sequencing Core.
10·Lentiviral stocks were generated by the University of
Michigan Vector Core.
Schwann cell culture and fatty acid preparation
Schwann cells were isolated from SCN of P3 rat pups as
previously described (35). Cells were plated on Primaria
surface-modified plates in Dulbecco’s Modification of Eagle’s
Medium (DMEM)/10% FBS. At confluence, fibroblasts were
removed by complement lysis by using thy1.1 antibody and
rabbit complement. Schwann cells were maintained in low
glucose (1 g/L) DMEM containing 10% heat-inactivated FBS,
2lM forskolin, 20 lg/ml bovine pituitary extract, and peni-
cillin/streptomycin/neomycin (feed media).
For lentiviral transduction, Schwann cells were incubated
in feed media containing 1·Acsl1-containing lentivirus con-
struct or empty vector for 24 h. Cells were then washed twice
with Hank’s balanced salt solution, fresh feed media was
added, and cells weremaintained for 7 days prior to treatment
experiments. During optimization experiments, transduction
efficiency was confirmed by visualization of mCherry fluo-
rescence every 2 days, and a Western immunoblot for Acsl1
protein was performed on day 7. Following confirmation that
mCherry fluorescence correlated with Acsl1 overexpression,
visual determination was used to confirm transduction effi-
ciency in all subsequent experiments.
Prior to LCFA treatment experiments, Schwann cells were
switched to defined media for 12 h (1:1 mix of low glucose
[1 g/L] DMEM and Ham’s F12K media containing 10lg/ml
transferrin, 10lM putrescine, 20 nM progesterone, and 30 nM
sodium selenite). Mitochondrial uptake of activated LCFAs is
facilitated through the temporary replacement of the CoA
group by carnitine (27). Carnitine (2mM) and CoA (200 lM)
were therefore added to culturemedia for the duration of high
LCFA incubations. For CellROX, TUNEL, and XF24 Analyzer
assays, Schwann cells were plated on poly-L-lysine-coated
coverslips and XF24 Analyzer culture plates.
A single, 100· solution of linoleate, oleate, and palmitate
(Nu-Chek Prep, Inc.) was prepared in 0.5% fatty acid-free
bovine serum albumin (Equitech-Bio, Inc.) in low glucose
DMEM heated to 37C and added to culture wells for a final
concentration of 100 lM. Treatment media were placed in a
water bath at 37C for 30min before they were added to cells.
LCFA treatment durations were 12 h unless otherwise stated.
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Subcellular fractionation and Western immunoblotting
Subcellular fractionation was performed based on the
methods of Arnoult et al. (2). Schwann cells were harvested in
isotonic mitochondrial buffer (MB: 210mM mannitol, 70mM
sucrose, 1mM EDTA, and 10mM HEPES [pH 7.5]) supple-
mented with the protease inhibitor mixture Complete (Roche
Molecular Biochemicals) and homogenized for 30–40 strokes
with a Dounce homogenizer. Samples were transferred to
Eppendorf centrifuge tubes, homogenized for a further 20
strokes with a 28 gauge needle, and centrifuged (500 g, 5min,
4C) to remove nuclei and unbroken cells. The resulting su-
pernatant was then centrifuged (10,000 g, 45min, 4C) to ob-
tain the heavy membrane fraction enriched for mitochondria,
and the resulting supernatant was collected as the cytosolic
fraction. Cytosolic and heavy membranes fractions (30 and
10 lg of protein, respectively) were subject to Western
immunoblotting.
Western immunoblotting was performed as previously
described (36–38). Polyclonal antibodies against long-chain
acyl-CoA synthetase 1 (Acsl1; Pierce Biotechnology),
glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Mil-
lipore), actin (Abcam), and anti-porin/voltage-dependent
anion channel (VDAC; Millipore) were used.
Real-time PCR
Assessment of mRNA for specific mitochondrial proteins
was performed by real-time PCR (RT-PCR) as previously
described (31). Reverse transcription was performed using
the iScript cDNA Synthesis kit (Bio-Rad). Real-time PCR
amplification and SYBR green fluorescence detection were
performed using the iCycler iQ Real-time Detection System
(Bio-Rad). The fluorescence threshold value (Ct) was
calculated using iCycler iQ system software. The mRNA
levels were normalized to an endogenous reference gene
(GAPDH, encoding glyceraldehyde-3-phosphate dehydro-
genase; DCt) and then relative to a control group (DDCt),
and were expressed as 2 -DDCt. The average was calculated
from two runs per sample.
Targeted metabolomic analysis by LC/MS/MS
Targeted metabolomic analysis was performed as previ-
ously described (12). Briefly, frozen Schwann cell sampleswere
extracted with 150ll of chilled 8:1:1 methanol:chloroform:
water containing 13C-labeled standards and chromatographic
separation of eight targeted metabolic intermediates was per-
formed based on the methods of Lorenz et al. (15). The ratio of
each metabolite peak area to that of the closest-matching 13C-
labeled standard was calculated. Metabolite concentration was
determined using calibration curves generated from known
concentrations of authentic standards and equal concentrations
of 13C-labeled compounds as were present in the samples.
Concentrations were normalized to cell counts from TUNEL
assays (number of cells per 20·objective field of view; four
fields of viewper coverslip; five coverslips per condition). Final
values are expressed as nmol/cell count.
Mitochondrial respiration and extracellular
acidification measures
The XF24 Extracellular Flux Analyzer (Seahorse Bios-
ciences) was used to measure bioenergetic function in intact
primary cultured Schwann cells. The XF24 culture plates al-
low simultaneous measurement of real-time OCR and ECAR
(indirect assessment of glycolytic activity due to lactic acid
production and proton extrusion) with negligible disruption
to the cells. Bioenergetic measurements using the XF24 Ana-
lyzer require buffer-free media, thus, 1 h prior to mitochon-
drial respiration measurements, media was changed to
unbuffered DMEM, supplemented with 1mM sodium pyru-
vate and 5.5mM D-glucose (pH 7.4). Based on initial opti-
mization experiments, Schwann cells were seeded at 2.5 · 105
cells per well 24 h prior to treatments. At this seeding density,
optimal concentrations of respiratory chain inhibitors oligo-
mycin and antimycin A were 1.25 and 1lM, respectively. An
FCCP (uncoupling protonophore) concentration of 300 nM
was determined to give maximal flux without significant
toxicity (data not shown). Following stable baseline OCR and
ECAR measurements, bioenergetic profile experiments were
performed by the sequential injection of oligomycin, FCCP,
and antimycin A. Loop Start, Mix, Wait, and Measure times
were 4, 3, 2, and 3min, respectively. ATP-linked oxygen
consumption, non-ATP-coupled mitochondrial oxygen con-
sumption (proton leak), maximal respiratory capacity, and
nonmitochondrial oxygen consumption were calculated from
the response curves (4, 22). Additional bioenergetic parame-
ters, including coupling efficiency, respiratory control ratio,
and spare respiratory capacity, were derived from the re-
sponse curves as described (4, 23).
Following mitochondrial respiration measurements, cells
were harvested and the protein concentration of each well
was determined for normalization of experimental rate values
to protein content. Bioenergetic profile respiration experi-
ments were repeated thrice, with 10 replicate measures (10
wells in the XF24 culture plate) per condition per experi-
mental repeat.
Mitochondrial DNA quantification
Levels of mtDNA were measured by normalizing the mi-
tochondrial gene (cytochrome b) to the nuclear gene (actin) as
previously described (9, 31). A total of 10 ng genomic DNA
was used for mtDNA and nuclear DNA markers.
Oxidative stress measures
SCN and Schwann cell samples were analyzed for nitrated
protein (3-nitrotyrosine) and oxidized lipids (HODEs) as
previously described (12).
CellROX Green Reagent (Invitrogen) is a cell-permeant dye
that exhibits bright green photostable fluorescence upon oxi-
dation byROS and subsequent binding toDNA. CellROXwas
applied to Schwann cells at a final concentration of 5lM for
30min at 37C. Cells were washed with PBS, fixed in 2%
paraformaldehyde, and mounted with ProLong antifade
mounting media containing dapi (Invitrogen). Green fluo-
rescence was imaged using the 488 nm filter and 20· objective
on a Nikon Microphot FXA fluorescent microscope.
TUNEL analysis
Cellular injury was assessed by counting the number of
TUNEL-positive cells identified using the ApopTag Perox-
idase In Situ Apoptosis Detection Kit as previously described
(37, 38). Mean values were calculated from four fields of view
598 HINDER ET AL.
per coverslip using a 20 · objective, with five coverslips per
condition.
Statistical analysis
Data analysis was performed using GraphPad Prism 5.0
(GraphPad Software). Comparisons between groups were
performed using one-way ANOVA with Tukey post-test for
multiple comparisons, two-way ANOVA with Bonferroni
post-test for multiple comparisons, or an unpaired t-test, as
applicable. Assumptions about the Gaussian distribution of
data and rules for transformation of non-normative data were
made as previously described (24). Significance was assigned
when p< 0.05.
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Abbreviations Used
Acsl1¼ long-chain acyl-CoA synthetase 1
CACT¼ carnitine/acylcarnitine translocase
Cpt1¼ carnitine palmitoyltransferase 1
Cpt2¼ carnitine palmitoyltransferase 2
DMEM¼Dulbecco’s Modification of Eagle’s Medium
DN¼diabetic neuropathy
ECAR¼ extracellular acidification rate
FCCP¼ carbonyl cyanide-p-trifluoromethoxyphenyl
hydrazone
GAPDH¼ glyceraldehyde-3-phosphate dehydrogenase
HODEs¼hydroxyoctadecadienoic acids
LCFAs¼ long chain fatty acids
LC/MS/MS¼ liquid chromatography triple quadrupole
mass spectrometry
OCR¼ oxygen consumption rate
ROS¼ reactive oxygen species
SCN¼ sciatic nerve
VLDL¼very low density lipoprotein
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